JP2002527387A5 - - Google Patents

Download PDF

Info

Publication number
JP2002527387A5
JP2002527387A5 JP2000575500A JP2000575500A JP2002527387A5 JP 2002527387 A5 JP2002527387 A5 JP 2002527387A5 JP 2000575500 A JP2000575500 A JP 2000575500A JP 2000575500 A JP2000575500 A JP 2000575500A JP 2002527387 A5 JP2002527387 A5 JP 2002527387A5
Authority
JP
Japan
Prior art keywords
ara
use according
dha
ratio
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000575500A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002527387A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP1999/007834 external-priority patent/WO2000021524A1/en
Publication of JP2002527387A publication Critical patent/JP2002527387A/ja
Publication of JP2002527387A5 publication Critical patent/JP2002527387A5/ja
Pending legal-status Critical Current

Links

JP2000575500A 1998-10-15 1999-10-15 Ｐｕｆａサプリメント Pending JP2002527387A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98308403.9 1998-10-15
EP98308403 1998-10-15
PCT/EP1999/007834 WO2000021524A1 (en) 1998-10-15 1999-10-15 Pufa supplements

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010268487A Division JP2011098966A (ja) 1998-10-15 2010-12-01 Ｐｕｆａサプリメント

Publications (2)

Publication Number Publication Date
JP2002527387A JP2002527387A (ja) 2002-08-27
JP2002527387A5 true JP2002527387A5 (https=) 2006-12-07

Family

ID=8235104

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000575500A Pending JP2002527387A (ja) 1998-10-15 1999-10-15 Ｐｕｆａサプリメント
JP2010268487A Pending JP2011098966A (ja) 1998-10-15 2010-12-01 Ｐｕｆａサプリメント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010268487A Pending JP2011098966A (ja) 1998-10-15 2010-12-01 Ｐｕｆａサプリメント

Country Status (13)

Country Link
US (2) US20070184090A1 (https=)
EP (4) EP1121115B2 (https=)
JP (2) JP2002527387A (https=)
CN (3) CN102090636A (https=)
AT (1) ATE361066T1 (https=)
AU (2) AU775421B2 (https=)
CA (2) CA2355341C (https=)
DE (1) DE69935995T3 (https=)
DK (1) DK1121115T4 (https=)
ES (1) ES2284286T5 (https=)
HK (1) HK1042441A1 (https=)
NZ (1) NZ511071A (https=)
WO (1) WO2000021524A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12156860B2 (en) 2011-04-26 2024-12-03 Biojiva Llc Disorders implicating PUFA oxidation

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
EP1911837B1 (en) 2000-09-28 2011-05-25 Bioriginal Food & Science Corp. FAD5-2 fatty acid desaturase family member and uses thereof
CA2442692A1 (en) 2001-03-30 2002-10-10 The Nisshin Oillio, Ltd. Bone metabolism improving agents
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
AU778384B2 (en) * 2001-11-14 2004-12-02 Virtus Nutrition Llc Method for manufacturing fatty acid calcium salts from high glyceride content oils
EP2255667A1 (en) * 2002-06-19 2010-12-01 DSM IP Assets B.V. Pasteurisation process for microbial cells and microbial oil
KR101195574B1 (ko) * 2002-09-24 2012-10-30 산토리 홀딩스 가부시키가이샤 아라키돈산을 단독으로 또는 도코사헥사엔산과의 조합으로함유하는 인지 능력 향상용 조성물
US20070037885A1 (en) * 2003-04-25 2007-02-15 Sandra Edwards Biomass containing animal feed
US8633246B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Omega-3 fatty acids for osteoarthritis
US8633247B2 (en) 2003-08-11 2014-01-21 Hill's Pet Nutrition, Inc. Method for decreasing cartilage damage in dogs
EA200602014A1 (ru) 2004-04-30 2007-08-31 ВИРТУС НЬЮТРИШН ЭлЭлСи Синтез солей одновалентных и двухвалентных металлов полиненасыщенных жирных кислот
JP5667737B2 (ja) * 2004-07-01 2015-02-12 ネステク ソシエテ アノニム イヌ変形性関節症食餌製剤
ES2253089B1 (es) * 2004-07-16 2007-08-16 Berthol Victor Laboratorios Ordesa, S.L. Complemento nutraceutico para la preparacion de leches infantiles.
JP2006083136A (ja) * 2004-09-17 2006-03-30 Suntory Ltd ストレスに起因する脳機能の低下およびそれに伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
EP2098229A4 (en) 2006-12-28 2010-03-10 Suntory Holdings Ltd NERVE REGENERATION MEDIUM
WO2009102558A2 (en) * 2008-02-11 2009-08-20 Monsanto Technology Llc Aquaculture feed, products, and methods comprising beneficial fatty acids
CN101259101B (zh) * 2008-04-17 2010-06-02 湖北福星生物科技有限公司 微米级花生四烯酸和二十二碳六烯酸乳状液及其制备方法
GB2460056A (en) * 2008-05-14 2009-11-18 Arab Science & Technology Foun Compositions comprising omega-6 fatty acids for use in treating schistosomiasis
CA2777827C (en) 2009-10-30 2020-08-18 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
AU2012249917B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Neurodegenerative disorders and muscle diseases implicating PUFAs
EP3689342A1 (en) * 2011-04-26 2020-08-05 Retrotope, Inc. Oxidative retinal diseases
AU2012249918B2 (en) 2011-04-26 2017-06-15 Biojiva Llc Impaired energy processing disorders and mitochondrial deficiency
EP2745706A1 (en) * 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Methods for maintaining bone quality
FI3626806T3 (fi) 2013-12-20 2024-08-22 Mara Renewables Corp Menetelmiä öljyn talteenottamiseksi mikro-organismeista
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
CA3005983A1 (en) 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1,4-diene systems
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
EP3559206B1 (en) 2016-12-22 2025-12-03 Mara Renewables Corporation Methods for producing biomass rich in dha, palmitic acid and protein using a eukaryotic microorganism
CA3172351A1 (en) 2020-02-21 2021-08-26 Retrotope, Inc. Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof
MX2022012322A (es) 2020-04-03 2022-11-10 Mara Renewables Corp Aceites microbianos con niveles altos de ácidos grasos omega-3.
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
AU2023337123A1 (en) * 2022-09-07 2025-04-03 Nourish Ingredients Pty Ltd Compositions and methods for producing meat-like aromas
WO2026020071A1 (en) * 2024-07-18 2026-01-22 Red Abbey Labs, Llc Autogenous therapeutic lipid carriers

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916734D0 (en) * 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
US5658767A (en) † 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
ES2157898T3 (es) 1991-01-24 2001-09-01 Martek Corp Aceites microbianos y usos de los mismos.
PH11992043811B1 (en) * 1991-01-24 2002-08-22 Martek Corp Arachidonic acid and methods for the production and use thereof
JPH0692848A (ja) * 1992-09-11 1994-04-05 Sagami Chem Res Center 糖尿病治療用乳剤
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
JPH06271464A (ja) * 1993-03-19 1994-09-27 Tokiwa Yakuhin Kogyo Kk 消化器系障害の予防または治療用アラキドン酸含有組成物
PT707487E (pt) * 1993-06-09 2004-08-31 Martek Biosciences Corp Metodos e composicoes farmaceuticas uteis no tratamento de disturbios neurologicos
JPH07267856A (ja) * 1994-02-09 1995-10-17 Green Cross Corp:The 経口免疫抑制剤
GB9510636D0 (en) * 1995-05-25 1995-07-19 Scotia Holdings Plc Fatty acid treatment
AU6252196A (en) * 1995-06-07 1996-12-30 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
US6200624B1 (en) * 1996-01-26 2001-03-13 Abbott Laboratories Enteral formula or nutritional supplement containing arachidonic and docosahexaenoic acids
ES2256882T5 (es) 1996-03-26 2012-12-17 Dsm Ip Assets B.V. Agregado tardío de pufa en el transcurso del proceso de preparación de una leche maternizada
EP0893953B1 (en) 1996-03-26 2002-06-05 Dsm N.V. Pufa coated solid carrier particles for foodstuff
JP4545235B2 (ja) 1996-03-28 2010-09-15 ディーエスエム アイピー アセッツ ビー．ブイ． 顆粒状微生物バイオマスの製造法とそのバイオマスからの貴重化合物の単離法
CN1217029A (zh) 1996-03-28 1999-05-19 吉斯特-布罗卡迪斯股份有限公司 从用巴氏法灭菌的生物量中制备含有微生物多不饱和脂肪酸的油的方法
FR2749133A1 (fr) * 1996-06-04 1997-12-05 Pierre Moreau Obtention d'oeufs specifiquement enrichis en acide cervonique (acide docosahexaenoique ou dha). applications alimentaires, therapeutiques et industrielles de ces oeufs et de leurs extraits lipidiques
JP3792309B2 (ja) * 1996-08-30 2006-07-05 サントリー株式会社 不飽和脂肪酸含有油脂の製造方法
JP4633204B2 (ja) * 1996-10-11 2011-02-16 サントリーホールディングス株式会社 アラキドン酸含有食用油脂およびそれを含有する食品

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12156860B2 (en) 2011-04-26 2024-12-03 Biojiva Llc Disorders implicating PUFA oxidation

Similar Documents

Publication Publication Date Title
JP2002527387A5 (https=)
WO2002011564A3 (en) Supplement for type 2 diabetes or lipodystrophy
Sorenson 6 copper complexes offer a physiological approach to treatment of chronic diseases
Keys et al. Fiber and pectin in the diet and serum cholesterol concentration in man.
JPH11199496A5 (https=)
CA2355341A1 (en) The use of ara as a supplement for a lactating woman
RU2350124C2 (ru) Питательная композиция для улучшения состояния кожи и предотвращения кожных заболеваний
CA2279791C (en) Dietary supplement combining colostrum and lactorferrin in a mucosal delivery format
CA2294099A1 (en) Absorption of minerals
CA2231292A1 (en) Method for decreasing ldl-cholesterol concentration and increasing hdl-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
MX2009001156A (es) Composiciones de vitamina d y metodo de administracion a un ser humano.
WO2001028526A3 (en) Gastroresistant tablets for alimentary, dietetic and therapeutic use
CA2285552A1 (en) Solid compositions suitable for oral administration comprising an alkanoyl-l-carnitine magnesium citrate
JP2003517456A5 (https=)
BG104286A (en) Composition for the suppression of the symptoms of withdrawal and irresistible desire for alcohol in alcoholics and prevention of alcohol addiction among healthy patients
US20130034630A1 (en) Reload energy gel for athletes and active adults
JP2005261376A (ja) キトサン含有補助食品
DE60318550D1 (de) Muttermilchzusatz
US6372264B1 (en) Method of reducing calcified arterial plaque buildup and cellular malfunction and for balancing ionic calcium
EP1121865A3 (en) A medical composition for the treatment and/or prevention of malnutrition
Khor et al. Cardiovascular risk factors among Malaysian urban vegetarians
Bartlett et al. WIC Participant and Program Characteristics, 1998
CN100387144C (zh) 一种微米金苡白药松花粉消食健脾豆浆粉制备方法
Winkvist et al. Malnourished Mothers Maintain their Weight Through out Pregnancy and Lactation: Results From Guatemala
Lantin Set your heart on eating well